CSPC Innovation Pharmaceutical (SHE:300765) subsidiary CSPC Jushi Biopharmaceutical's phase 3 trial for its SYS6010 lung cancer drug reached its primary endpoint of progression-free survival, according to a Thursday disclosure to the Shenzhen Stock Exchange.
The drug exhibited better progression-free survival than current treatments, with statistically and clinically significant differences, as well as good safety, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments